Eli Lilly says it won't be sweetening its offer for SGX Pharmaceuticals. The company says its bid of $3 a share, which had doubled the stock's value, was its best and final offer. Shareholders vote August 20. Report
Eli Lilly says it won't be sweetening its offer for SGX Pharmaceuticals. The company says its bid of $3 a share, which had doubled the stock's value, was its best and final offer. Shareholders vote August 20. Report